Bibliography
- Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96
- Wilt TJ, MacDonald R, Rutks I, et al. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008;148:435-48
- Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int 2008;102:1531-8
- Antonarakis ES, Blackford AL, Garrett-Mayer E, Eisenberger MA. Survival in men with nonmetastatic prostate cancer treated with hormone therapy: a quantitative systematic review. J Clin Oncol 2007;25:4998-5008
- Thompson I, Thrasher JB, Aus G, et al. AUA prostate cancer clinical guideline update panel. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007;177:2106-31
- Loblaw DA, Virgo KS, Nam R, et al. American society of clinical oncology. Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American society of clinical oncology practice guideline. J Clin Oncol 2007;25:1596-605
- Seidenfeld J, Samson DJ, Hasselblad V, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med 2000;132:566-77
- McLeod DG. Hormonal therapy: historical perspective to future directions. Urology 2003;61(2 Suppl 1):3-7
- Burgus R, Butcher M, Ling N, et al. Molecular structure of the hypothalamic factor (LRF) of ovine origin monitoring the secretion of pituitary gonadotropic hormone of luteinization (LH). C R Acad Sci Hebel Seances Acad Sci D 1971;273:1611-13
- Matsuo H, Baba Y, Nair RM, et al. Structure of the porcine LH- and FSH-releasing hormone. I. The proposed amino acid sequence. Biochem Biophys Res Commun 1971;43:1334-9
- Labrie F, Bélanger A, Luu-The V, et al. Gonadotropin-releasing hormone agonists in the treatment of prostate cancer. Endocr Rev 2005;26:361-79
- Charlton H. Hypothalamic control of anterior pituitary function: a history. J Neuroendocrinol 2008;20:641-6
- Cook T, Sheridan WP. Development of GnRH antagonists for prostate cancer: new approaches to treatment. Oncologist 2000;5:162-8
- Eder IE, Culig Z, Putz T, et al. Molecular biology of the androgen receptor: from molecular understanding to the clinic. Eur Urol 2001;40:241-51
- Schally AV, Redding TW, Comaru-Schally AM. Inhibition of prostate tumors by agonistic and antagonistic analogs of LH-RH. Prostate 1983;4:545-52
- Doehn C, Jocham D. Technology evaluation: Abarelix, Praecis pharmaceuticals. Curr Opin Mol Ther 2000;2:579-85
- Doehn C, Sommerauer M, Jocham D. Drug evaluation: degarelix–a potential new therapy for prostate cancer. Drugs 2006;9:565-72
- Bajusz S, Kovacs M, Gazdag M, et al. Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects. Proc Natl Acad Sci USA 1988;85:1637-41
- Jiang G, Stalewski J, Galyean R, et al. GnRH antagonists: a new generation of long acting analogues incorporating p-Ureido-phenylalanines at position 5 and 6. J Med Chem 2001;44:453-67
- Broqua P, Riviere PJM, Conn PM, et al. Pharmacological profile of a new, potent and long-acting gonadotropin-releasing hormone antagonist: degarelix. J Pharmacol Exp Ther 2002;301:95-102
- Schwach G, Oudry N, Delhomme S, et al. Biogradable microparticles for sustained release of a new GnRH antagonist – part I: screening commercial PLGA and formulation technologies. Eur J Pharm Biopharm 2003;56:327-36
- Schwach G, Oudry N, Giliberto JP, et al. Biogradable PLGA microparticles for sustained release of a new GnRH antagonist: part II. In vivo performance. Eur J Pharm Biopharm 2004;40:441-6
- Agerso H, Koechling W, Knutsson M, et al. The dosing solution influence on the pharmacokinetics of degarelix, a new GnRH antagonist, after sc administration to beagle dogs. Eur J Pharm Sci 2003;20:335-40
- Tornøe CW, Agerso H, Nielsen HA, et al. Population pharmacokinetic modeling of a subcutaneous depot for GnRH antagonist degarelix. Pharm Res 2004;21:574-84
- Tornøe CW, Agersø H, Nielsen HA, et al. Pharmacokinetic/pharmacodynamic modelling of GnRH antagonist degarelix: a comparison of the non-linear mixed-effects programs NONMEM and NLME. J Pharmacokinet Pharmacodyn 2004;31:441-61
- Weston PMT, Hammonds J, Vaughton Olesen TK, et al. Degarelix; a novel GnRH antagonist tested in a multicentre, randomized dose-finding study in prostate cancer patients. BJU Int 2004;94(Suppl 2):57
- Tammela T, Iversen P, Johansson J, et al. Degarelix Study group. Degarelix; a phase II multicenter, randomised dose-escalating study testing a novel GnRH receptor blocker in prostate cancer patients. Eur Urol Suppl 2005;4:228
- Gittelman M, Pommerville PJ, Persson BE, et al. Degarelix Study Group. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. J Urol 2008;180:1986-92
- Van Poppel H, Tombal B, de la Rosette JJ, et al. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker – results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. Eur Urol 2008;54:805-13
- Plenaxis (abarelix for injectable suspension). Available from: www.fda.gov/Cder/Drug/infopage/plenaxis/default.htm [Last accessed 20 February 2009]
- Speciality European Pharma. Available from: www.specialityeuropeanpharma.com [Last accessed 20 February 2009]
- Degarelix. Available from: www.fda.gov/cder/Offices/OODP/whatsnew/Degarelix.htm [Last accessed 20 February 2009]
- Huggins C, Stevens RE Jr, Hodges CV. Studies on prostate cancer. II. The effect of castration on advanced carcinoma of the prostate gland. Arch Surg 1941;43:209-23
- Montironi R, Magi-Galluzzi C, Muzzonigro G, et al. Effects of combination endocrine treatment on normal prostate, prostatic intraepithelial neoplasia, and prostatic adenocarcinoma. J Clin Pathol 1994;47:906-13
- Castellón E, Clementi M, Hitschfeld C, et al. Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma. Cancer Invest 2006;24:261-8
- Bubley GJ. Is the flare phenomenon clinically significant? Urology 2001;58(2 Suppl 1):5-9
- Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008;300:173-81
- Cooperberg MR, Moul JW, Carroll PR. The changing face of prostate cancer. J Clin Oncol 2005;23:8146-51
- Sharifi N, Gulley JL, Dahut WL. Androgen deprivation therapy for prostate cancer. JAMA 2005;294:238-44
- Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448-56
- Mottet N, Prayer-Galetti T, Hammerer P, et al. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. BJU Int 2006;98:20-7
- Potosky AL, Knopf K, Clegg LX, et al. Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. J Clin Oncol 2001;19:3750-7
- Saigal CS, Gore JL, Krupski TL, et al. The urologic diseases in America project. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007;110:1493-500
- Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009;6:76-85
- Oefelein MG, Feng A, Scolieri MJ, et al. Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making. Urology 2000;56:1021-4
- Boustead G, Edwards SJ. Systematic review of early vs deferred hormonal treatment of locally advanced prostate cancer: a meta-analysis of randomized controlled trials. BJU Int 2007;99:1383-9
- de Jong IJ, Eaton A, Bladou F. LHRH agonists in prostate cancer: frequency of treatment, serum testosterone measurement and castrate level: consensus opinion from a roundtable discussion. Curr Med Res Opin 2007;23:1077-80
- Morote J, Orsola A, Planas J, et al. Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy. J Urol 2007;178:1290-5
- Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med 2005;352:154-64
- Smith MR, Malkowicz SB, Chu F, et al. Toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer: interim analysis of a multicenter phase 3 clinical study. J Urol 2008;179:152-5